Advertisement

Cardiovascular Drugs and Therapy

, Volume 6, Issue 1, pp 11–14 | Cite as

Early and late proarrhythmia from antiarrhythmic drug therapy

  • Joel Morganroth
State-of-the-Art Lectures

Summary

Antiarrhythmic drug therapy is used with the hope of suppressing arrhythmias and therefore decreasing their associated symptoms or prolonging life. Unfortunately, many antiarrhythmic drugs have the opposite effect of exacerbating or provoking arrhythmias, a phenomenon that is termed proarrhythmia when such an event is specifically due to the drug in use. Early proarrhythmic events (within 30 days of initiation of drug use) have been reasonably well characterized and are predicted by either type of drug employed or the nature of the patient's cardiac disease and arrhythmia type. Late proarrhythmic events, as defined by placebo-controlled trials, have now been recognized as an increased risk of arrhythmic death in patients on antiarrhythmic drugs after many months of therapy. Initially, this late proarrhythmic event was identified with encainide and flecainide, but now several new studies have demonstrated that the risk of late proarrhythmia of comparable magnitude may be present in patients subjected to commonly used drugs, such as quinidine, mexelitine, etc. At present, only moricizine and the class II drugs (β-adrenergic blockers) appear not to have this potential late proarrhythmic response. Therefore, before instituting antiarrhythmic drug therapy, the physician must be able to quantitate the degree of proarrhythmia and other risks of such therapy, as compared to their potential benefit, to define the proper indications for these agents.

Key Words

proarrhythmia sudden cardiac death antiarrhythmic agents 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Withering W. An account of the foxglove and some of its medical uses with practical remarks on dropsy and other diseases. Birmingham, England: M. Sweeney, 1785.Google Scholar
  2. 2.
    Selzer A, Wray HW. Quinidine syncope: Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964;30:17–26.PubMedGoogle Scholar
  3. 3.
    Velebit V, Podrid P, Lown B, et al. Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 1982;65:886–894.PubMedGoogle Scholar
  4. 4.
    Morganroth J, Horowitz LN. Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984;53:89B-94B.PubMedCrossRefGoogle Scholar
  5. 5.
    Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987;59:32E-37E.PubMedCrossRefGoogle Scholar
  6. 6.
    Morganroth J, Borland M, Chao G. Application of frequency definition of ventricular proarrhythmia. Am J Cardiol 1987;59:97–99.PubMedCrossRefGoogle Scholar
  7. 7.
    Ray AP, Kay HR, Horowitz LN, et al. Proarrhythmic effects of antiarrhythmic drugs in patients with malignant ventricular arrhythmias evaluated by electrophysiologic testing. J Am Coll Cardiol 1988;12:131–139.CrossRefGoogle Scholar
  8. 8.
    Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986;8:607–615.PubMedCrossRefGoogle Scholar
  9. 9.
    Morganroth J. Premature ventricular complexes: Diagnosis and indications for therapy. JAMA 1984;252:673–676.PubMedCrossRefGoogle Scholar
  10. 10.
    The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Increased mortality due to encainide or flecainide in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406–412.CrossRefGoogle Scholar
  11. 11.
    Morganroth J, Pratt C. Prevalence and characteristics of proarrhythmia from moricizine (ethmozine). Am J Cardiol 1989;63:172–176.PubMedCrossRefGoogle Scholar
  12. 12.
    Morganroth J, Goin JE, Brozovich FV. Increased mortality from quinidine therapy in the treatment of ventricular arrhythmias. J Am Coll Cardiol 1991;17:387A.Google Scholar
  13. 13.
    Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta analysis of randomized clinical trials. Circulation 1990;82:1106–1116.PubMedGoogle Scholar
  14. 14.
    Anderson JL. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic therapy after the Cardiac Arrhythmia Suppression Trial. J Clin Pharmacol 1990;30:981–989.PubMedGoogle Scholar
  15. 15.
    Yusuf S, Petor, Lewis J, et al. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–371.PubMedCrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Joel Morganroth
    • 1
    • 2
  1. 1.University of Pennsylvania School of MedicinePhiladelphia
  2. 2.The Philadelphia Heart Institute of the Presbyterian Medical CenterPhiladelphia

Personalised recommendations